09:14 AM EST - Oncolytics Biotech Inc : Announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET study has met the efficacy expansion criteria for Stage 1 of the trial. The data from the phase 1b portion of this cohort are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2022, and show a strong efficacy signal as evidenced by all patients achieving a partial response. The trial's metastatic colorectal and advanced anal cancer cohorts are proceeding as planned. Oncolytics Biotech Inc
shares T.ONC are trading up $0.06 at $1.36.
